Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Director dealings: Croda counsel's associate invests almost £0.1m
(Sharecast News) - Croda International was at the top of the buyers' list on Tuesday, after it disclosed a purchase worth almost £0.1m linked to its general counsel. The FTSE 100 company said Sarah Brophy bought 1,401 of its shares at 7,099p each on 10 March, making the purchase worth £99,456.93.
Sarah Brophy was linked in the disclosure to Croda's company secretary and group general counsel, Tom Brophy.
On the selling side of the ledger, meanwhile, were some high-value transactions, with Hikma Pharmaceuticals reporting that its chief executive officer Sigurdur Olafsson had sold 16,299 shares.
The FTSE 100 firm said Olafsson sold the shares for 1,988p each, netting him £324,024.11 to cover his tax bill after vesting 26,377 incentive plan award shares.
PageGroup also disclosed share sales to cover HMRC liabilities, with chief executive officer Steve Ingham selling 92,047 shares and chief financial officer Kelvin Stagg selling 45,813 shares, both at a price of 493.4p each.
The FTSE 250 company said Ingham's £454,159.90 sale covered his tax and national insurance bill after he received 195,354 incentive shares, while Stagg had £226,041.34 to send to the revenue after receiving 97,228 shares.
Top Director Buys
Croda International (CRDA) Director name: Brophy ,Tom Amount purchased: 1,401 @ 7,099.00p Value: £99,456.93
Novacyt S.a. (cdi) (NCYT) Director name: McCarthy,James Amount purchased: 37,310 @ 201.00p Value: £74,993.10
Lancashire Holdings Limited (LRE) Director name: Kershaw,Natalie Amount purchased: 12,438 @ 401.87p Value: £49,984.59
Novacyt S.a. (cdi) (NCYT) Director name: McCarthy,James Amount purchased: 2,360 @ 212.00p Value: £5,003.20
British Land Company (BLND) Director name: Carter,Simon Amount purchased: 30 @ 508.12p Value: £152.44
British Land Company (BLND) Director name: Mistry,Bhavesh Amount purchased: 30 @ 508.12p Value: £152.44
Bae Systems (BA.) Director name: Woodburn,Charles Amount purchased: 20 @ 743.82p Value: £148.76
Bae Systems (BA.) Director name: Greve,Brad Amount purchased: 20 @ 743.82p Value: £148.76
Emis Group (EMIS) Director name: Southby,Peter Amount purchased: 12 @ 1,210.00p Value: £145.20
Top Director Sells
Hikma Pharmaceuticals (HIK) Director name: Olafsson,Sigurdur Amount sold: 27,498 @ 1,988.00p Value: £546,660.22
Pagegroup (PAGE) Director name: Ingham,Stephen Amount sold: 92,047 @ 493.40p Value: £454,159.90
Hikma Pharmaceuticals (HIK) Director name: Olafsson,Sigurdur Amount sold: 16,299 @ 1,988.00p Value: £324,024.11
Pagegroup (PAGE) Director name: Stagg ,Kelvin Amount sold: 45,813 @ 493.40p Value: £226,041.34
Derwent London (DLN) Director name: George,Nigel Q Amount sold: 2,474 @ 3,090.46p Value: £76,457.98
Derwent London (DLN) Director name: Williams,Paul M. Amount sold: 2,474 @ 3,090.46p Value: £76,457.98
Derwent London (DLN) Director name: Silverman,David Amount sold: 2,474 @ 3,090.46p Value: £76,457.98
Reach (RCH) Director name: Fuller,Simon Amount sold: 42,005 @ 178.42p Value: £74,945.74
Chemring Group (CHG) Director name: Lewis,Andrew Amount sold: 18,000 @ 333.94p Value: £60,109.20
Derwent London (DLN) Director name: Williams,Paul M. Amount sold: 1,881 @ 3,090.46p Value: £58,131.55
Derwent London (DLN) Director name: Silverman,David Amount sold: 1,601 @ 3,090.46p Value: £49,478.26
Derwent London (DLN) Director name: George,Nigel Q Amount sold: 1,601 @ 3,090.46p Value: £49,478.26
Derwent London (DLN) Director name: Wisniewski,Damian Amount sold: 1,601 @ 3,090.46p Value: £49,478.26
Derwent London (DLN) Director name: Prideaux,Emily Amount sold: 676 @ 3,090.46p Value: £20,891.51
Ilika (IKA) Director name: Boydell,Stephen John Amount sold: 2,000 @ 118.00p Value: £2,360.00
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.